Plot­ting a come­back af­ter 2016 flop, Seres to raise $100M to prep C. dif­fi­cile pro­gram for launch

Mi­cro­bio­me pi­o­neer Seres Ther­a­peu­tics faced nu­mer­ous set­backs through­out the years in nu­mer­ous fields, most promi­nent­ly for its lead pro­gram in C. dif­fi­cile in­fec­tions. But the biotech has plot­ted a come­back af­ter a ma­jor flop six years ago, and is con­fi­dent enough to start seek­ing cash ahead of a pos­si­ble mar­ket launch.

Seres on Thurs­day said it plans to raise $100 mil­lion by of­fer­ing stock pur­chas­es to new and ex­ist­ing in­vestors, giv­ing the com­pa­ny some mon­ey to pre­pare for com­mer­cial ac­tiv­i­ty and ad­di­tion­al man­u­fac­tur­ing ca­pa­bil­i­ties. The biotech of­fered the shares $MCRB at $3.15 apiece, equal to Wednes­day’s clos­ing price.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER